Application of peptide nucleic acid in cancer therapy

Anti-Cancer Drugs

Volumn 8, Issue 2, 1997, Pages 113-118

  Knudsen, Helle ^a   Nielsen, Peter E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti gene; Antisense; Cancer therapy; PNA

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; DNA; PEPTIDE NUCLEIC ACID; RNA;

CANCER THERAPY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031055255     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199702000-00002     Document Type: Review

References (57)

1. Agrawal S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 1996; 14: 376-87.
2. Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia 1996; 50: 168-76.
3. Tidd DM. Specificity of antisense oligonucleotides. Perspect Drug Discovery Design 1996; 4: 51-60.
4. Agrawal S, Iyer RP Modified oligonucleotides as therapeutic and diagnostic agents. Curr Biol 1995; 6: 129.
5. Sharma HW, Nurayanan R. The therapeutic potential of antisense oligonucleotides BioAssays 1995; 17: 1055-63.
6. Stein CA, Narayanan R. Antisense oligodeoxynucleotides. Curr Opni Oncol 1994; 6: 587-94.
7. Egholm M, Buchardt O, Christensen L, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson -Crick hydrogen-bonding rules. Nature 1993; 365: 566-8.
8. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 149-500.
9. Egholm M, Buchardt O, Nielsen PE, Berg RH. Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J Am Chem Soc 1992; 114: 1895-7.
10. Egholm M, Nielsen PE, Buchardt O, Berg RH. Recognition of guanine and adenine in DNA by cytosine and thymine containing peptide nucleic acids (PNA). J Am Chem Soc 1992; 114: 9677-8.
11. Nielsen PE, Egholm M, Buchardt O. Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone. Bioconjugate Chem 1994; 5: 3-7
12. Leijon M, Graslund A, Nielsen PE, et al. Structural characterization of PNA-DNA duplexes by NMR Evidence for DNA in a B-like conformation. Biochemistry 1994; 33: 9820-5.
13. Brown SC, Thomson SA, Veal JM, Davis DG. NMR solution structure of a peptide nucleic acid complexed with RNA. Science 1994; 265: 777-80.
14. 8 and poly(dA) shown by linear and circular dichroism spectroscopy. J Am Chem Soc 1993; 115: 6477-81.
15. 2/DNA triplex structure upon binding of PNA to dsDNA by strand displacement. J Mol Recognit 1994; 7: 165-70.
16. Cherny DY, Belotserkovskii BP, Frank-Kamenetskii MD, et al. DNA unwinding upon strand-displacement binding of a thymine-substituted polyamide to double-stranded DNA. Proc Natl Acad Sci USA 1993; 90: 1667-70.
17. Nielsen PE, Egholm M, Berg RH, Buchardt O. Peptide nucleic acids (PNAs): potential antisense and anti-gene agents. Anti-Cancer Drug Design 1993; 8: 53-63.
18. Jensen KK, Ørum H, Nielsen PE, Norden B. Hybridization kinetics of peptide nucleic acids (PNA) with DNA and RNA studied with BIAcore technique. Submitted.
19. Christensen L, Fitzpatrick R, Gildea B, et al. Solid-phase synthesis of peptide nucleic acids J Peptide Sci 1995; 3: 175-83.
20. Hyrup B, Nielsen PE. Peptide nucleic acids (PNA). Synthesis, properties and potential applications. Bioorg Biomed Chem 1996; 4: 5-23.
21. Eriksson M, Nielsen PE. PNA nucleic acid complexes. Structure, stability and dynamics. Quart Rer Biophys 1996; in press.
22. Giles RV, Ruddell CJ, Spiller DG, Green JA, Tidd DM. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res 1995; 23: 954-61.
23. Walder RY, Walder JA. Role of RNase H in hybridarrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 1988; 85: 5011-5.
24. Knudsen H, Nielsen PE. Antisense properties of duplix- and triplex-forming PNAs. Nucleic Acids Res 1996; 24: 494-500.
25. Stetsenko DA, Lubyako EN, Potapov VK, Azhikina TL, Sverdlov ED. New approach to solid phase synthesis of polyamide nucleic acid analogues (PNA) and PNA - DNA conjugates. Tetrahedron Lett 1996; 37: 3571-4.
26. Finn PJ, Gibson NJ, Fallon P Hamilton A, Brown T. Synthesis and properties of DNA-PNA chimeric oligomers. Nucleic Acids Res 1996; 24: 3357-64.
27. van der Laan AC, Meeuwenoord NJ, Kuyl-Yeheskiely E, Oosting RS, Brands R, van Boom JH. Solid support synthesis of a PNA-DNA hybrid. Rectteil des Tra-veaux Chimiques des Pays-Bas 1995; 114: 295-7.
28. Bergmann F, Bannwarth W, Tam S. Solid phase synthesis of directly linked PNA-DNA hybrids. Tetrahedron Lett 1995; 36: 6823-6.
29. Hanvey JC, Peffer NJ, Bisi JE, et al. Antisense and antigene properties of peptide nucleic acids. Science 1992; 258: 1481-5.
30. Gambacorti-Passerini C, Mologni L, Bertazzoli C, et al. In vitro transcription and translation inhibition by anti-Promyelocytic Leukemia (PML)/Retinoic acid receptor α and anti-PML peptide nucleic acid. Blood 1996; 88: 1411-7.
31. Bonham MA, Brown S, Boyd AL, et al. An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res 1995; 23: 1197-203.
32. Nielsen PH, Egholm M, Buchardt O. Sequence-specific transcription arrest by nucleic acid bound to the DNA template strand, Gene 1994; 149: 139-45.
33. Demidov VV, Nielsen PE. Unpublished data.
34. Egholm M, Christensen L, Dueholm KL, Buchardt O, Coull J, Nielsen PE. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosinecontaining bis-PNA. Nucleic Acids Res 1995; 23: 217-22.
35. Bentin T, Nielsen PE. Enhanced peptide nucleic acid binding to supercoiled DNA: possible implications for 'breathing' dynamics, Biochemistry 1996; 35: 8863-9.
36. Ljungman M, Hanawalt PC. Presence of negative torsional tension in the promoter region of transcriptionally poised dihydropholate reductase gene in vivo. Nucleic Acids Res 1995; 23: 1782-9.
37. Jupe ER, Sinden RR, Cartwright IL. Stably maintained microdomain of localized unrestrained supercoiling at a Drosophila heat shock gene locus. EMBO J. 1993; 12: 1067-75.
38. Larsen HJ, Nielsen PE. Transcription-mediated binding of peptide nucleic acid (PNA) to double stranded DNA: sequence-specific suicide transcription. Nucleic Acids Res 1996; 24: 458-63.
39. Vickers TA, Griffith MC, Ramasamy K, Risen LM, Freier SM. Inhibition of NF-ΚB specific transcriptional activation by PNA strand invation. Nucleic Acids Res 1995; 23: 3003-8.
40. Praseuth D, Grigoriev M, Guieysse A, et al. Peptide nucleic acids directed to the promotor of the α-chain of the promotor of the interleukin 2 receptor Biochem Biophys Acta 1996; 1309: 226-38
41. Boffa LC, Morris PL, Carpaneto EM, Louissaint M, Allfrey VG. Invasion of the CAG triplet repeats by a complementary peptide nucleic acid inhibits transcription of the androgen receptor and TATA-binding protein genes and correlates with refolding of an active nuclcosome containing a unique AR gene sequence, J Biol Chem 1996; 271: 13228-33.
42. Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR. Inhibition of human telomerase activity by peptide nucleic acids Nature Biotechnol 1996; 14: 615-9.
43. Knudsen H and Nielsen PE. Unpublished data.
44. Demidov VV, Potaman VN. Frank-Kamenetskii MD, et al. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol 1994; 48: 1310-3.
45. Leonetti C, D'Agnano I. Lozupone F, et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice J Natl Cancer Inst 1996; 88: 419-29.
46. Huang Y, Snyder R, Kligshteyn M, Wickstrom E. Prevention of tumor formation in a mouse modes of Burkitt's lymphoma by 6 weeks of treatment with antic-myc DNA phosphorothioate. Mol Med 1995; 1: 647-58.
47. Chavany C, Connell Y, Neckers L. Contribition of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers Mol Pharmacol 1995; 48: 738-46.
48. Burgess TL, Fisher EH, Ross SL, et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism Proc Natl Acad Sci USA 1995; 92: 4051-5.
49. Citro G, Szczylik C, Ginobbi P, Zupi G, Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myc antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer 1994; 69: 463-7.
50. Ratajczak MZ, Kant JA, Luger SM, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1992; 89: 11823-7.
51. Schwab G, Chavany C, Doroux I, et al. Antisense oligonucleotides absorbed to polyalkylcyanoacrylate nonoparticles specifically inhibit mutated Ha-rasmediated cell proliferation and tumorgenieity in nude mice. Proc Natl Acad Sci USA 1994; 91: 10460-4.
52. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E. Antisense DNA inhibition of tumor growth by c-Ha-ras oncogene in nude mice. Cancer Res 1993; 53: 577-80.
53. Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Therapy 1995; 2: 207-12.
54. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994; 4: 71-9.
55. Vaerman JL, Lammineur C, Moureau P, et al. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism Blood 1995; 86: 3891-6.
56. Chasty R, Whetton A, Lucas G. A comparison of the effect of bcr/abl breakpoint specific phosphorothioate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations. Leukemia Res 1996; 20: 391-5.
57. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D. Antitumor activity of a phosphorothioate antisense oligonucleotide targeted against C-raf kinase. Nature Medicine 1996; 2: 668-75.